Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05328908 · ClinicalTrials.gov registry record · Phase 3
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 770
- Enrollment target
NCT05328908 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 770 participants.
The verdict
NCT05328908, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 770 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC) participants who failed at least 1 but no more than 4 prior lines of therapy for metastatic disease.
Interventions
- DRUG Regorafenib
- DRUG TAS-102
- DRUG Nivolumab-relatlimab FDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2025-07-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05328908
The ClinicalTrials.gov registry entry for NCT05328908 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 770 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Regorafenib is the first listed.
NCT05328908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05328908 about?
NCT05328908 is a clinical study titled "A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer". The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorect...
What is the current status of trial NCT05328908?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 770 participants. The study started on 2022-04-28. Estimated completion is 2025-07-14.
What interventions are being tested in trial NCT05328908?
The interventions under investigation include: Regorafenib (DRUG), TAS-102 (DRUG), Nivolumab-relatlimab FDC (DRUG).
Who is sponsoring clinical trial NCT05328908?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.